Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Bifidobacterium species are widely studied probiotics with a moderate level of scientific evidence supporting their use as adjunctive therapy in Inflammatory Bowel Disorders (IBD), particularly ulcerative colitis and, to a lesser extent, Crohn’s disease. Clinical trials and meta-analyses have shown that certain Bifidobacterium strains (often in combination with other probiotics in multi-strain preparations like VSL#3) can help induce or maintain remission in ulcerative colitis, reduce inflammation, and improve symptoms. The proposed mechanisms include modulation of the gut microbiota, enhancement of the intestinal barrier, inhibition of pathogenic bacteria, and regulation of immune responses (e.g., reducing pro-inflammatory cytokines).

However, results vary depending on the specific species, strain, dosage, and patient population studied. For instance, Bifidobacterium longum and Bifidobacterium breve have demonstrated some efficacy in small clinical studies, but the evidence is less robust and consistent for Crohn’s disease compared to ulcerative colitis. Systematic reviews and guidelines generally consider probiotics, including Bifidobacterium, as potentially beneficial adjuncts but not as primary or standalone therapies for IBD.

Overall, the scientific evidence supports a moderate benefit (evidence rating: 3/5), with the greatest support for use in ulcerative colitis. Larger and more rigorous trials are needed to clarify the efficacy of specific Bifidobacterium strains in IBD and to identify which patients are most likely to benefit.

More about Bifidobacterium (various species)
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Bifidobacterium (various species)

Products containing Bifidobacterium (various species)